From the blog

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Primary Outcome Measures Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE) [ Time Frame: Up to 3 weeks ] DLTs will be assessed during the first cycle (21 days) and are defined as Grade (Gr) 4 hematologic toxicities (any period), except neutropenia[…]

Read More »

There is a Possible New Way to Diagnose Pleural Mesothelioma

Researchers have possibly found a less invasive way to diagnose pleural mesothelioma. By looking at the patient’s medical history and using CT scans, researchers at the Universite Laval in Quebec have found that imaging technology can be used potentially to benefit very sick patients. Doctors have never been able to[…]

Read More »

Lung Cancer Awareness Month Starts Today

Today starts Lung Cancer Awareness Month. In November, we come together to recognize this deadly cancer and learn about different causes and treatments. Knowing the different statistics and causes could help save a lot of people’s lives. Lung cancer is the leading cause of death due to cancer in men[…]

Read More »